Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 439-443

  Aydin, Meryem Ulku ^a,b   Aygul, Nazif ^c   Altunkeser, Bulent Behlul ^c   Unlu, Ali ^c   Taner, Alpaslan ^d  

^a Servergazi State Hospital   (Turkey)

^b DENIZLI STATE HOSPITAL   (Turkey)

^c SELCUK UNIVERSITY   (Turkey)

^d Section of Radiology   (Turkey)

Author keywords

Atorvastatin; Inflammatory markers; Lipid parameters; Oxidized LDL; Rosuvastatin; ST segment elevation myocardial infarction

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; AUTACOID; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IL6 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN; TNFRSF1A PROTEIN, HUMAN; TNFRSF1B PROTEIN, HUMAN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; METABOLISM; MYOCARDIAL INFARCTION; TREATMENT OUTCOME; TURKEY;

AGED; ATORVASTATIN CALCIUM; BIOMARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME; TURKEY;

EID: 84922985034     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.02.003     Document Type: Article

References (32)

1. Granger C.B., Weaver W.D. Reducing cardiac events after acute coronary syndromes. Rev. Cardiovasc. Med. 2004, 5(Suppl.5):S39-S46.
2. Shin J., Edelberg J.E., Hong M.K. Vulnerable atherosclerotic plaque: clinical implications. Curr. Vasc. Pharmacol. 2003, 1(2):183-204.
3. Williams K.J., Tabas I. The response to retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidol. 1998, 9(5):471-474.
4. Ross R. The pathogenesis of atherosclerosis - an update. N.Engl. J. Med. 1986, 314(8):488-495.
5. Brunetti N.D., Troccoli R., Correale M., et al. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int. J. Cardiol. 2006, 109(2):248-256.
6. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high dose atorvastatin in patients with acute coronary syndrome. J.Am. Coll. Cardiol. 2005, 46(8):1405-1410.
7. McTaggart F., Buckett L., Davidson R., et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 2001, 87(5A):28B-32B.
8. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(1):3-46. European Society of Cardiology (ESC), European Atherosclerosis Society (EAS)European Atherosclerosis Society (EAS).
9. Scott M.G., Hidenori A., Philip B., et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report. J.Clin. Lipidol. 2014, 8(1):29-60.
10. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285(13):1711-1718.
11. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J.Am. Coll. Cardiol. 2014, 63(25Pt B):2889-2934.
12. Bertram P., Joseph L., John M., et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am. J. Cardiol. 2012, 109(9):1239-1246.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Execuative summary of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel). JAMA 2001, 285(19):2486-2497.
14. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295(13):1556-1565. ASTEROID Investigators.
15. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J.Lipid Res. 2004, 45(6):993-1007.
16. Johnston N., Jernberg T., Lagerqvist B., et al. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. Am. J. Cardiol. 2006, 97(5):640-645.
17. Holvoet P., Harris T.B., Tracy R.P., et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study. Arterioscler. Thromb. Vasc. Biol. 2003, 23(8):1444-1448.
18. Liu M.L., Ylitalo K., Salonen R., et al. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler. Thromb. Vasc. Biol. 2004, 24(8):1492-1497.
19. Holvoet P., Vanhaecke J., Janssens S., et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98(15):1487-1494.
20. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J.Clin. Invest. 2002, 110(3):285-288.
21. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N.Engl. J. Med. 2005, 352(1):29-38.
22. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373(9670):1175-1182.
23. Kerr R., Stirling D., Ludlam C.A. Interleukin 6 and haemostasis. Br. J. Haematol. 2001, 115(1):3-12.
24. No author listed Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention study (WOSCOPS). Circulation 1998, 97(15):1440-1445.
25. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
26. Biasucci L.M., Bitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94(5):874-877.
27. Stefanadi E., Tousoulis D., Antoniades C., et al. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. Int. J. Cardiol. 2009, 133(2):266-268.
28. Barath P., Fishbein M.C., Cao J., et al. Detection and localization of tumor necrosis factor in human atheroma. Am. J. Cardiol. 1990, 65(5):297-302.
29. Ridker P.M., Rifai N., Pfeffer M., et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101(18):2149-2153.
30. Higuchi Y., McTiernan C.F., Frye C.B., et al. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 2004, 109(15):1892-1897.
31. Ferro D., Parotto S., Basilli S., et al. Simvastatin inhibit the monocyte expression of proinflammotary cytokines in patients with hypercholesterolemia. J.Am. Coll. Cardiol. 2000, 36(2):427-431.
32. Mozaffarian D., Minami E., Letterer R.A., et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am. J. Cardiol. 2005, 96(12):1699-1704.